The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter.,Clinical Cancer Research

当前位置： X-MOL 学术 › Clin. Cancer Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter.
Clinical Cancer Research ( IF 10.0 ) Pub Date : 2020-01-15 , DOI: 10.1158/1078-0432.ccr-19-2441
Alessandro Di Federico ₁ , Daria M Filippini ₁ , Filippo G Dall'Olio ₁ , Nicole Conci ₁ , Roberta Minari ₂ , Marcello Tiseo ₂ , Andrea Ardizzoni ₁

Affiliation

We read with interest the recently published paper by Truini and colleagues ([1][1]) describing the peculiar in vitro activity of afatinib on non–small cell lung cancer cell lines harboring the EGFR L747-A750>P mutation. We reviewed our patient database and found 6 cases out of 265 with this

中文翻译：

EGFR外显子19突变体L747-A750> P对肺腺癌信件中的酪氨酸激酶抑制剂表现出不同的敏感性。

我们感兴趣地阅读了Truini及其同事最近发表的论文（[1] [1]），该论文描述了阿法替尼对具有EGFR L747-A750> P突变的非小细胞肺癌细胞系的特殊体外活性。我们审查了患者数据库，发现265例患者中有6例

更新日期：2020-01-15

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11